ANDA 200540, held by Exela Holdings. Diclofenac Sodium; Misoprostol.
As of Nov 19, 2026, ANDA 200540 (Diclofenac Sodium and Misoprostol), held by Exela Holdings, was first approved by FDA on Mar 14, 2014, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 14, 2014 | Original application | Approved | None posted |
| Diclofenac Sodium and Misoprostol50MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Discontinued |
| Diclofenac Sodium and Misoprostol75MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Discontinued |
| Dec 27, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 27, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 27, 2017 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 14, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters